Drugs & Therapy Perspectives

, Volume 24, Issue 6, pp 13–16 | Cite as

Early detection and individualized treatment of elderly-onset systemic lupus erythematosus optimizes symptom control

Disease Management
  • 39 Downloads

References

  1. 1.
    Gladman D, Urowitz M. Clinical features of systemic lupus erythematosus. In: Hochberg M, Silman A, Smolen J, et al, editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 417–37Google Scholar
  2. 2.
    Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging 2007; 24(9): 701–15PubMedCrossRefGoogle Scholar
  3. 3.
    Kammer GM, Mishra N. Systemic lupus erythematosus in the elderly. Rheum Dis Clin North Am 2000; 26(3): 475–92PubMedCrossRefGoogle Scholar
  4. 4.
    Freedman GM. Chronic pain: clinical management of common causes of geriatric pain. Geriatrics 2002; 57(5): 36–41PubMedGoogle Scholar
  5. 5.
    Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11(6): 340–7PubMedCrossRefGoogle Scholar
  6. 6.
    Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45(3): 531–9PubMedCrossRefGoogle Scholar
  7. 7.
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324(3): 150–4CrossRefGoogle Scholar
  8. 8.
    Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10(3): 140–7PubMedCrossRefGoogle Scholar
  9. 9.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44(7): 1496–503CrossRefGoogle Scholar
  10. 10.
    Aranow C, Ginzler EM. Treatment of constitutional symptoms, skin, joint, serositis, cardio-pulmonary, hematologic and central nervous system manifestations In: Hochberg M, Stilman A, Smolen J, et al., editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 439–48Google Scholar
  11. 11.
    Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353(21): 2219–28PubMedCrossRefGoogle Scholar
  12. 12.
    Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314(10): 614–9PubMedCrossRefGoogle Scholar
  13. 13.
    Krensky AM, Vincenti F, Bennett WM. Immunosuppressants, tolerogens, and immunostimulants. In: Brunton LL, editor in chief. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies, Inc., 2006: 1405–31Google Scholar
  14. 14.
    Van Vollenhoven RF, Morabito LM, Engleman AG, et al. Treatment of systemic lupus erythematous with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25(2): 285–9Google Scholar
  15. 15.
    Rauova L, Likac J, Rovensky J, et al. High-dose intravenous immunoglobulins for lupus nephritis: salvage immunomodulation. Lupus 2001; 10: 209–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations